Anticancer Ruthenium Complexes with HDAC Isoform Selectivity

Cross, J.M.; Blower, T.R.; Kingdon, A.D.H.; Pal, R.; Picton, D.M.; Walton, J.W.

Abstract

The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms may lead to unwanted side-effects. In this paper, we show that piano stool Ru complexes can act as HDAC inhibitors, and variation in the capping arene leads to differences in HDAC isoform selectivity.

Citation

Cross, J., Blower, T., Kingdon, A., Pal, R., Picton, D., & Walton, J. (2020). Anticancer Ruthenium Complexes with HDAC Isoform Selectivity. Molecules, 25(10), Article 2383. https://doi.org/10.3390/molecules25102383

• Journal Article Type: Article
• Acceptance Date: May 16, 2020
• Online Publication Date: May 21, 2020
• Publication Date: May 2, 2020
• Deposit Date: May 18, 2020
• Publicly Available Date: May 22, 2020
• Journal: Molecules
• Electronic ISSN: 1420-3049
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 25
• Issue: 10
• Article Number: 2383
• DOI: https://doi.org/10.3390/molecules25102383
• Public URL: https://durham-repository.worktribe.com/output/1270488